Scientist receives $4.9 million CIRM grant to advance work in retinitis pigmentosa

NewsGuard 100/100 Score

Shaomei Wang, MD, PhD, a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute, received a $4.9 million grant from the California Institute for Regenerative Medicine (CIRM) to advance her work in retinitis pigmentosa, a type of degenerative retinal disease.

Retinitis pigmentosa erodes the cells in the retina, the light-sensitive area in the back of the eye. Symptoms typically begin with poor night vision in young adults and progress to legal blindness by age 40 to 50. There is currently no cure for the disease that affects 150,000 individuals nationally.

"Funding from CIRM will spur the late stages of preclinical projects necessary to bring our treatment to patients," said Wang, who leads the Wang Laboratory.

These preclinical studies center on an injection into the eye of human neural progenitor cells. Once injected into the eye, these cells migrate long distances along the retina and end up adjacent to photoreceptors. They are then able to slow down the progressive retinal degeneration and preserve vision in animal models of retinal degeneration.

"This project represents many years of previous work using these cells," said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute. "We are extremely excited that CIRM is providing this new financial support for this novel approach to delaying the degeneration of retinal cells in this devastating disease."

The primary goal of the Wang Laboratory is to increase understanding of degenerative retinal diseases and develop treatments. Preclinical studies within this laboratory have already led to three clinical trials using stem cells to treat macular degeneration.

Cedars-Sinai grant collaborators include Alexander Ljubimov, PhD, and Kent Small, MD, both part of the Eye Program in the Cedars-Sinai Board of Governors Regenerative Medicine Institute.

Prior to the $4.9 million grant awarded to Wang, the Cedars-Sinai Regenerative Medicine Institute has received 14 grants totaling more than $43 million from CIRM .

Comments

  1. Grace Mukli-Stelmaschuk Grace Mukli-Stelmaschuk Canada says:

    Is this for human clinical trials?  Is it a generic trial or specific to certain mutations?  Are the candidates selected?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the ‘immune self,’ and how can this concept benefit immunological research?